Agenus/$AGEN
1D1W1MYTD1Y5YMAX
About Agenus
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
- Ticker
- $AGEN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 81
- Headquarters
- Lexington, United States
- Website
- www.agenusbio.com
Agenus Metrics
BasicAdvanced
$376M
3.34
$2.51
1.40
-
Price and volume
Market cap
$376M
Beta
1.4
52-week high
$8.85
52-week low
$2.71
Average daily volume
1.8M
Financial strength
Current ratio
0.34
Quick ratio
0.319
Long term debt to equity
-4.633
Total debt to equity
-19.776
Interest coverage (TTM)
0.60%
Profitability
EBITDA (TTM)
40.61
Gross margin (TTM)
113.61%
Net profit margin (TTM)
69.34%
Operating margin (TTM)
27.04%
Revenue per employee (TTM)
$1,640,000
Management effectiveness
Return on assets (TTM)
12.53%
Return on equity (TTM)
-33.92%
Valuation
Price to earnings (TTM)
3.337
Price to revenue (TTM)
2.294
Price to book
-1.79
Price to tangible book (TTM)
-1.58
Price to free cash flow (TTM)
-3.09
Free cash flow yield (TTM)
-32.36%
Free cash flow per share (TTM)
-2.706
Growth
Revenue change (TTM)
30.47%
Earnings per share change (TTM)
-136.68%
3-year revenue growth (CAGR)
10.13%
10-year revenue growth (CAGR)
17.24%
3-year earnings per share growth (CAGR)
-46.92%
10-year earnings per share growth (CAGR)
-19.05%
What the Analysts think about Agenus
Analyst ratings (Buy, Hold, Sell) for Agenus stock.
Agenus Financial Performance
Revenues and expenses
Agenus Earnings Performance
Company profitability
Agenus News
AllArticlesVideos
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Business Wire3 weeks ago
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
Business Wire4 weeks ago
Agenus shares surge as company secures up to $340M to advance colon cancer trial
Proactive Investors1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.